Thyroid cancer

Summary Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the stand...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2016-12, Vol.388 (10061), p.2783-2795
Main Authors: Cabanillas, Maria E, Dr, McFadden, David G, MD, Durante, Cosimo, MD
Format: Article
Language:English
Subjects:
Carcinoma, Neuroendocrine - diagnosis
Carcinoma, Neuroendocrine - diagnostic imaging
Carcinoma, Neuroendocrine - surgery
Clinical trials
Diagnosis, Differential
Disease-Free Survival
Humans
Internal Medicine
Iodine
Iodine radioisotopes
Kinases
Metastasis
Mutation
Severity of Illness Index
Thyroid
Thyroid cancer
Thyroid Neoplasms - diagnosis
Thyroid Neoplasms - diagnostic imaging
Thyroid Neoplasms - genetics
Thyroid Neoplasms - physiopathology
Thyroid Neoplasms - surgery
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(16)30172-6